Bayer AG’s OTC pain relief category had sales growth of 9% in the third quarter and its allergy and cold segment's sales increased 6.4% as its consumer health business shows some recovery while it continues implementing turnaround strategies.
Bayer Sees Light At End Of Consumer Turnaround Tunnel: Q3 Sales Grow 3.7%
Bayer consumer health segment shows 3.7% growth to $1.43bn on 9% growth in pain relief and 6.4% in allergy and cold. But North American business still faces challenges.
More from Earnings
• By
Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
More from Business
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.